Vitrolife AB Total Liabilities
Vitrolife AB total liabilities. Based on the latest financial reports, Vitrolife AB (VITR) has total liabilities worth Skr3.17 Billion SEK (≈ $340.82 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check VITR asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Vitrolife AB (2000–2025)
Total liabilities of Vitrolife AB from 2000 to 2025. This chart illustrates how Vitrolife AB's total liabilities have evolved over time, based on quarterly financial data. Explore VITR long-term investments to assets to see how much of total assets are deployed in long-term investments.
Vitrolife AB Competitors by Total Liabilities
The table below lists competitors of Vitrolife AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grupo Aval Acciones y Valores S.A
F:6GAA
|
Germany | €315.97 Trillion |
|
Kemper Corporation
NYSE:KMPR
|
USA | $9.75 Billion |
|
Bank of Chongqing Co Ltd
F:CQN
|
Germany | €967.73 Billion |
|
RAPT Therapeutics Inc
NASDAQ:RAPT
|
USA | $13.76 Million |
|
Sanhe Tongfei Refrigeration Co. Ltd.
SHE:300990
|
China | CN¥675.50 Million |
|
Greentown China Holdings Limited
F:G7C
|
Germany | €344.15 Billion |
|
Sila Realty Trust, Inc.
NYSE:SILA
|
USA | $772.30 Million |
|
PG Electroplast Limited
NSE:PGEL
|
India | Rs-30.49 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Vitrolife AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Vitrolife AB (VITR) total assets.
Liquidity & Leverage Metrics
Vitrolife AB Total Liabilities Ratios Explained
Vitrolife AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vitrolife AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vitrolife AB (2000–2025)
The table below shows the annual total liabilities of Vitrolife AB from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr3.23 Billion ≈ $347.49 Million |
-15.14% |
| 2024-12-31 | Skr3.81 Billion ≈ $409.48 Million |
+5.52% |
| 2023-12-31 | Skr3.61 Billion ≈ $388.06 Million |
-5.38% |
| 2022-12-31 | Skr3.81 Billion ≈ $410.12 Million |
-6.77% |
| 2021-12-31 | Skr4.09 Billion ≈ $439.93 Million |
+1319.05% |
| 2020-12-31 | Skr288.07 Million ≈ $31.00 Million |
-15.54% |
| 2019-12-31 | Skr341.06 Million ≈ $36.70 Million |
+69.47% |
| 2018-12-31 | Skr201.25 Million ≈ $21.66 Million |
+3.86% |
| 2017-12-31 | Skr193.78 Million ≈ $20.85 Million |
-15.79% |
| 2016-12-31 | Skr230.11 Million ≈ $24.76 Million |
+7.39% |
| 2015-12-31 | Skr214.27 Million ≈ $23.06 Million |
-20.61% |
| 2014-12-31 | Skr269.91 Million ≈ $29.05 Million |
+63.38% |
| 2013-12-31 | Skr165.21 Million ≈ $17.78 Million |
-9.83% |
| 2012-12-31 | Skr183.22 Million ≈ $19.72 Million |
+49.11% |
| 2011-12-31 | Skr122.88 Million ≈ $13.22 Million |
+19.23% |
| 2010-12-31 | Skr103.06 Million ≈ $11.09 Million |
+118.12% |
| 2009-12-31 | Skr47.25 Million ≈ $5.08 Million |
-6.02% |
| 2008-12-31 | Skr50.27 Million ≈ $5.41 Million |
+9.11% |
| 2007-12-31 | Skr46.08 Million ≈ $4.96 Million |
-8.57% |
| 2006-12-31 | Skr50.40 Million ≈ $5.42 Million |
+44.32% |
| 2005-12-31 | Skr34.92 Million ≈ $3.76 Million |
-0.13% |
| 2004-12-31 | Skr34.96 Million ≈ $3.76 Million |
-13.80% |
| 2003-12-31 | Skr40.56 Million ≈ $4.36 Million |
-47.40% |
| 2002-12-31 | Skr77.11 Million ≈ $8.30 Million |
-10.65% |
| 2001-12-31 | Skr86.30 Million ≈ $9.29 Million |
+114.93% |
| 2000-12-31 | Skr40.15 Million ≈ $4.32 Million |
-- |
About Vitrolife AB
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware … Read more